Swiss National Bank Increases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Swiss National Bank lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 13.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,873 shares of the company’s stock after buying an additional 5,100 shares during the period. Swiss National Bank owned about 0.09% of Enliven Therapeutics worth $942,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in Enliven Therapeutics by 10.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock worth $6,520,000 after purchasing an additional 24,043 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Enliven Therapeutics by 25.6% in the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after buying an additional 3,518 shares in the last quarter. FMR LLC raised its stake in shares of Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after buying an additional 601,611 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Enliven Therapeutics by 12.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock worth $668,000 after buying an additional 2,944 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Enliven Therapeutics in the 3rd quarter valued at about $2,539,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. BTIG Research assumed coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 target price on the stock. HC Wainwright upped their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $38.75.

Insider Activity

In other news, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the completion of the sale, the chief operating officer now owns 323,310 shares in the company, valued at approximately $6,931,766.40. This trade represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the firm’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total transaction of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company’s stock, valued at approximately $20,665,399.68. The trade was a 1.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 70,434 shares of company stock valued at $1,558,673 in the last 90 days. 29.20% of the stock is currently owned by insiders.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $21.07 on Friday. The firm has a market cap of $1.03 billion, a P/E ratio of -11.09 and a beta of 1.04. Enliven Therapeutics, Inc. has a 1 year low of $15.96 and a 1 year high of $30.03. The firm’s 50 day moving average price is $21.28 and its 200 day moving average price is $23.74.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.